The ClinGen Pharmacogenomics Working Group (PGxWG) has launched a survey to solicit feedback about the criteria and terminology that should be used to define clinical validity and actionability for pharmacogenes and variants.
The ClinGen PGxWG is a multi-disciplinary team of researchers and professionals with expertise in pharmacogenomics (PGx), clinical pharmacology, medical genetics, regulatory affairs, and molecular diagnostics. It was launched in February 2022 with the goal of developing a framework of tiered standard terminology and definitions that reflect clinical significance for genes and genomic variants implicated in drug response, in order to facilitate the incorporation of PGx knowledge into ClinGen and more consistent interpretation of PGx variants identified by panel testing and/or sequencing.
The survey is open now and can be accessed at: https://stanforduniversity.qualtrics.com/jfe/form/SV_bKqeKf2YmCVS1LM. All responses are greatly appreciated, no matter who you are or where you are in the world. This survey does assume some PGx familiarity, though we plan to launch another survey targeting those with less PGx experience in the near future. The survey takes approximately 10 minutes to complete. We sincerely appreciate your time and attention, and your willingness to help.